UroGen Pharma Ltd. Preferred Stock Dividends, Income Statement Impact
UroGen Pharma Ltd. (URGN) reported Preferred Stock Dividends, Income Statement Impact of $825.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2020-03-02
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for the quarter ending 2017-12-31 was $0.00.
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for the quarter ending 2017-09-30 was $1.00K.
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for the quarter ending 2017-06-30 was $216.00K.
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for the quarter ending 2017-03-31 was $602.00K.
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for fiscal 2017 was $825.00K, a 66.56% decline from fiscal 2016.
- UroGen Pharma Ltd. preferred stock dividends, income statement impact for fiscal 2016 was $2.47M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $1.00K derived: sum of 2 quarters · filed 2020-03-02 | $217.00K derived: sum of 3 quarters · filed 2020-03-02 | $825.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $217.00K derived: sum of 2 quarters · filed 2018-11-13 | $825.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $216.00K 6-K · filed 2018-08-14 | $824.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $602.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $2.47M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $852.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |